Università degli Studi di Torino. Ruolo del fattore trascrizionale FoxO-3 nei progenitori CD34+ Ph positivi nella leucemia mieloide cronica (LMC)

Similar documents
Il controllo della malattia minima residua Daniela Cilloni Università di Torino

G-TRACE: rapid Gal4-based cell lineage analysis in Drosophila

ELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.

X P. Supplementary Figure 1. Nature Medicine: doi: /nm Nilotinib LSK LT-HSC. Cytoplasm. Cytoplasm. Nucleus. Nucleus

Chronic Myeloid Leukemia Outlook: The Future of CML Therapy

J Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION

CML EHA: what s new? Novità dall EHA >> [ Leucemia mieloide cronica ] Relatore: G. MARTINELLI. Borgo S. Luigi Monteriggioni (Siena) ottobre 2008

Outlook CML 2016: What is being done on the way to cure

CML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML

mirna Dr. S Hosseini-Asl

Institute of Hematology and Medical Oncology L. e A. Seragnoli Bologna Italy

Cell Cycle and Cancer

How I treat high risck CML

number Done by Corrected by Doctor Maha Shomaf

Dati sulla sospensione della terapia

Characteristics of Cancer Stem Cells (CSCs)

Leucemia Mieloide Cronica: la terapia con imatinib

When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany

p53, CLIC, AND THE JAK/STAT PATHWAY: INVESTIGATING THE LINK BETWEEN CANCER STRESSES AND CELL DEATH IN DROSOPHILA MELANOGASTER

Follicular Lymphoma. ced3 APOPTOSIS. *In the nematode Caenorhabditis elegans 131 of the organism's 1031 cells die during development.

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT)

NEW DRUGS IN HEMATOLOGY

Lecture 8 Neoplasia II. Dr. Nabila Hamdi MD, PhD

EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

Determination Differentiation. determinated precursor specialized cell

MicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL

Metastasis progression

Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018

Chronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE

Allogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Chapt 15: Molecular Genetics of Cell Cycle and Cancer

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

Venice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann

A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.

Regulation of Cell Division (Ch. 12)

Mitosis and the Cell Cycle

Regulation of Cell Division. AP Biology

Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia

Division Ave. High School AP Biology

Chronic Myeloid Leukaemia

oncogenes-and- tumour-suppressor-genes)

Oncogenes and tumour suppressor genes

Regulation of Cell Division

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)

Chapter 12. Regulation of Cell Division. AP Biology

Molecular pathogenesis of CML: Recent insights

A class of genes that normally suppress cell proliferation. p53 and Rb..ect. suppressor gene products can release cells. hyperproliferation.

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC

609G: Concepts of Cancer Genetics and Treatments (3 credits)

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib

Validation & Assay Performance Summary

Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy

TARGETED THERAPY FOR CHILDHOOD CANCERS

CML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL

Minireview Shrinkage control: regulation of insulin-mediated growth by FOXO transcription factors Thomas P Neufeld

Karyotype analysis reveals transloction of chromosome 22 to 9 in CML chronic myelogenous leukemia has fusion protein Bcr-Abl

Haematopoietic stem cells

Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body

Management of CML in blast crisis. Lymphoma Tumor Board November 27, 2015

SESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy

Emerging" hallmarks of cancer, a. Reprogramming of energy metabolism b. Evasion of the immune system, Enabling characteristics, a.

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Overview of mathematical biological models and their application in CML research

Molecular Hematopathology Leukemias I. January 14, 2005

LAL: significato clinico e biologico delle mutazioni di Bcr-Abl

The BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

JAK2 V617F analysis. Indication: monitoring of therapy

Part II The Cell Cell Division, Chapter 2 Outline of class notes

Supplementary Appendix

Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil

Chapter 12 The Cell Cycle

Effective Targeting of Quiescent Chronic Myelogenous

Contents. Preface XV Acknowledgments XXI List of Abbreviations XXIII About the Companion Website XXIX

1.5. Research Areas Treatment Selection

CHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009

10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. Masahiro Kizaki Editor

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Dysregulation of Blimp1 transcriptional repressor unleashes p130cas/erbb2 breast cancer invasion (SREP T) Supplementary File

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Cancer. October is National Breast Cancer Awareness Month

Molecular Characterization of Leukemia Stem Cell Development. Scott A. Armstrong MD, Ph.D.

EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED

Developing Better Medicine

Molecular Medicine: Gleevec and Chronic Myelogenous Leukemia

Immunology CANCER IMMUNOLOGY

Section D. Genes whose Mutation can lead to Initiation

IRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

LESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2

Cancer and Oncogenes Bioscience in the 21 st Century. Linda Lowe-Krentz October 11, 2013

DETERMINANT VALUE OF THE CYTOGENETIC AND MOLECULAR IMATINIB THERAPEUTIC RESPONSE IN CHRONIC MYELOID LEUKEMIA

Transcription:

Università degli Studi di Torino Ruolo del fattore trascrizionale FoxO-3 nei progenitori CD34+ Ph positivi nella leucemia mieloide cronica (LMC) Francesca Messa Forkhead family CBP?? Ub Ub CBP Ub Ac Ac Ac UbUb AcAc? Ub Ac Forkhead family of transcription factors (39 members, 19 subgroups) Highly conserved across species (C.elegans, Drosophila, Mammals) Vary degrees of expression in all mammals tissue (FoxO1: adipose tissue;foxo3/6 nervouse tissue; FoxO4:developing brain) Wide range of roles during development (from organogenesis to language acquisition) 1

FoxO regulation Greer, 2005 FoxO target genes and cellular roles Differentiation Metabolism Apoptosis Cell Cycle inhibition Oxidative-stress resistance Modified from Greer, 2005 2

FoxO in cancer development Reagan-Shaw, 2007 Tumor suppressor FoxO inactivation in many cancer type (breast cancer, prostate cancer, glioblastoma) Involved in chromosomal translocations in tumors LOF of FoxOs in conditional KO models results in tumorigenesis in a highly tissue dependent and selective manner FoxO in leukemia Greer, 2005 3

FoxO and the HSC compartment FoxO and the HSC compartment 4

FoxO and Malignant Stem Cells Aim of the study To clarify the role of FoxO3 in Bcr-Abl induced apoptotic arrest and cell growth To investigate the role of FoxO3 and the effects of Imatinib treatment in CML progenitor cells 5

FoxO3 is delocalyzed in the cytoplasm in CML patients CML CP CML CCyR CTRL CML#1 CTRL CML#2 FoxO-3 C N C N C N α-tubulin lamin Abnormal cytoplasmatic localization of FoxO3 in CML patients leads to the abrogation of FoxO3 functions CTRL#1 CTRL#2 CML#1 2.00 100000 d e r p S t!c! - 2 1.75 1.50 1.25 1.00 0.75 0.50 0.25 BCR-ABL copies/ 10 4 ABL copies 2 -ΔΔct SPRED 10000 1000 100 10 1 0,6 0,5 0,4 0,3 0,2 0,1 0.00 0 ES MCyR CCyR MR m m 6

% APOPTOSIS 20 10 0 Re-localization of FoxO-3 reduces proliferation and induces apoptosis in K562 cell line *** ** *** ** K562 CTRL K562 FOXO WT K562 FOXO TM 12500 0 % INHIBITION PROLIFERATION 10000 20 40 7500 60 5000 80 2500 1000 ** *** *** FoxO3 K562 CTRL K562 CTRL+IM K562 FOXO WT K562 FOXO WT+IM K562 FOXO TM K562 FOXO TM+IM Lamin Actin FoxOs signalling is highly conserved across species Drosophila InR Mammals dpten dp110 dakt1 P P P dfoxo PTEN FoxO1 FoxO3 FoxO4 FoxO6 7

To demonstrate that BCR-ABL is responsible for FoxO inactivation The UAS-GAL4 binary system X Tissue specific enhancer TATA GAL4 UUUUUUUUUU AAAAAAAAAA Human Bcr-Abl p210 Tissue specific enhancer TATA GAL4 UUUUUUUUUU AAAAAAAAAA Human Bcr-Abl p210 8

FoxOgmrG4/ is directly uas bcr-abl 1M inactivated by hbcr-abl gmrg4, uas dfoxo/uas lacz gmrg4, uas dfoxo/uas bcr-abl 1M CD47 expression, a marker of proliferant cells, decreased in CD34+ cells from CML patients CD34 progenitor cells Untreated Imatinib 1 µm Imatinib 83% Ctrl 99% ARA-C 80% CML primary cells FoxO3 re-activation induces quiescence of progenitor cells compartment CD47 expression Imatinib 1µM CML CD34+ cells 9

In quiescent LSC FoxO-3 is localyzed within the nucleus Lyn+ CD34+ CD38+ Lyn- CD34+ CD38- There is a LSC pool in which quiescence is maintained by active form of FoxO3 FoxO and LSC IMATINIB Therapeutic resistance? 10

To further investigate if FoxO3 could be responsable for therapeutic resistance in Bcr-Abl transformed LSC The UAS-GAL4 binary system X Tissue specific enhancer TATA GAL4 UUUUUUUUUU AAAAAAAAAA Human Bcr-Abl p210 Tissue specific enhancer TATA GAL4 UUUUUUUUUU AAAAAAAAAA Human Bcr-Abl p210 11

Drosophila Lymph Gland CORTICAL ZONE, containing maturing hemocytes POSTERIOR SIGNALING CENTER, containing small cluster of signaling cells MEDULLARY ZONE, containing prohemocytes Dorsal vessel Pericardial cells, separarting each lobe Primary lobe Secondary lobes Bcr-Abl expression into fly lymph gland induced the formation of melanotic tumors SrpG4/UAS Bcr-Abl 4M 3 rd larval instar CgG4/UAS Bcr-Abl 3M 0-5 days adult fly 12

Next studies To analyze the role of FoxO3 in the quiescence and in the mainteinance of LSC using the Drosophila lymph gland as model system ACKNOWLEDGMENTS San Luigi Hospital University of Turin Daniela Cilloni Giuseppe Saglio Cristina Panuzzo Francesca Arruga Monica Pradotto Emanuela Messa Enrico Bracco Elisabetta Greco Chiara Maffè Sonia Carturan Antonia Rotolo University of Bologna Roberto Bernardoni Seragnoli Institute University of Bologna Michele Baccarani Giovanni Martinelli Ilaria Iacobucci 13